Virtu Financial LLC Buys Shares of 14,639 Cibus, Inc. (NASDAQ:CBUS)

Virtu Financial LLC purchased a new position in Cibus, Inc. (NASDAQ:CBUS) in the third quarter, Holdings Channel reports. The fund purchased 14,639 shares of the company’s stock, valued at approximately $48,000.

Several other institutional investors have also made changes to their positions in CBUS. SG Americas Securities LLC acquired a new position in Cibus in the 3rd quarter valued at approximately $33,000. HighTower Advisors LLC grew its holdings in shares of Cibus by 20.6% during the 3rd quarter. HighTower Advisors LLC now owns 16,125 shares of the company’s stock valued at $52,000 after acquiring an additional 2,750 shares in the last quarter. Barclays PLC increased its stake in shares of Cibus by 287.2% in the third quarter. Barclays PLC now owns 20,269 shares of the company’s stock worth $66,000 after acquiring an additional 15,034 shares during the last quarter. FineMark National Bank & Trust raised its holdings in shares of Cibus by 24.3% during the second quarter. FineMark National Bank & Trust now owns 20,488 shares of the company’s stock worth $202,000 after acquiring an additional 4,000 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Cibus during the second quarter worth $214,000. 33.81% of the stock is currently owned by institutional investors and hedge funds.

Cibus Price Performance

Shares of NASDAQ:CBUS opened at $2.64 on Friday. The stock has a market capitalization of $69.84 million, a P/E ratio of -0.12 and a beta of 1.86. The business has a 50-day moving average of $4.16 and a two-hundred day moving average of $6.28. Cibus, Inc. has a fifty-two week low of $2.37 and a fifty-two week high of $23.18.

Analysts Set New Price Targets

Several research analysts have weighed in on CBUS shares. Alliance Global Partners dropped their target price on Cibus from $25.00 to $23.50 and set a “buy” rating on the stock in a research report on Tuesday, September 24th. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Cibus in a report on Monday, November 11th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 target price on shares of Cibus in a research note on Tuesday, October 22nd.

Cibus Company Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.